We’re changing the shape of cataract surgery.

Be part of the transformation.

The Light Adjustable Lens (LAL®) is the first and only lens that can be adjusted in the eye, after cataract surgery. Precise UV light treatments adjust the shape of the Light Adjustable Lens, giving your patients truly custom vision that is literally transformative. Imagine what the LAL could do for your practice.

How the Light Adjustable Lens Is Different

The Light Adjustable Lens has revolutionized cataract surgery moving the important decisions about final lens power to its ideal place: after surgery. This way, the process can be more precise than ever, accounting for lens shift and refractive changes during the healing process, to achieve the best possible outcome.

We know the Light Adjustable Lens is a switch from the usual method of choosing from pre-manufactured lens powers before surgery to hit your patients’ post-surgery targets. To support this switch, the accuracy of the Light Adjustable Lens has been documented in clinical studies.

The LAL corrects down to 0.5 diopters of astigmatism, which is the lowest level approved to be treated.
The LAL offers LASIK-like accuracy in cataract surgery.
The LAL provides optimized vision for patient satisfaction.

Adjust for Infinite Possibilities

The Light Adjustable Lens is a versatile premium lens that a growing number of surgeons are finding is customizable for many types of patients. Throughout the adjustment process, Light Adjustable Lens patients are engaged and participate in their care in a way other lenses can’t offer.

This truly customized approach has led to outcomes they and their doctors are excited about. Almost daily, we add to the list of clinics nationwide that are successfully integrating the Light Adjustable Lens into their workflow and finding that it is a worthwhile investment for their practices and their patients.

How the Light Adjustable Lens Works

The Light Adjustable Lens is implanted using a standard cataract procedure. Patients then experience their vision and surgeons can adjust the lens over a series of treatments to ensure each patient achieves vision that matches their lives. Each adjustment is a UV light treatment performed by the Light Delivery Device (LDD®) that corrects refractive error and dials in optimized vision.

Macromers/polymers are not visible in the lens, and graphic is used only as an illustration.

The Importance of ActivShield Technology

ActivShield is a UV protection layer built into the Light Adjustable Lens. Along with UV glasses, ActivShield helps prevent accidental sunlight exposure from changing the lens prior to the final lock-in treatment.

ActivShield UV Protector
Play Video

Don’t Get Left in the Dark

Discover More About the Light Adjustable Lens

Join us in changing the shape of cataract surgery; fill out the form below to receive our complete guide to the Light Adjustable Lens.

HCP Download
Light Adjustable Lens brochure cover
  1. Watanabe K, Negishi K, Kawai M, et al. Effect of experimentally induced astigmatism on functional, conventional, and low-contrast visual acuity. J Refract Surg. 2013;29(1):19-24.
  2. RxSight P160055: FDA Summary of Safety and Effectiveness Data. 2017.
  3. Sandoval HP, Donnenfeld ED, Kohnen T, et al. Modern laser in situ keratomileusis outcomes. J Cataract Refract Surg. 2016;42(8):1224-1234.
LAL patients saw nearly as well without glasses (UCDVA) as control patients did with glasses (BCDVA).

The LAL provides optimized vision for patient satisfaction.2

LAL patients saw nearly as well without glasses (UCDVA) as control patients did with glasses (BCDVA).

Since the LAL is a monofocal lens, there is low risk of dysphotopsias caused by splitting light, leading to potentially enhanced vision and patient satisfaction.

LAL patients are approximately two times more likely to achieve 20/20 vision or better without glasses at 6 months.

The LAL offers LASIK-like accuracy in cataract surgery.2,3

92% of eyes (N = 391) achieved results within 0.50 D of target manifest refraction spherical equivalent (MRSE).

Patients are approximately two times more likely to achieve 20/20 vision or better without glasses at 6 months.

The study was a prospective, controlled, multicenter, 12-month study of 600 patients (ITT population) randomized to receive implantation with the RxSight LAL (N = 403) or a commercially available monofocal IOL (N = 197). Effectiveness analyses included 391 LAL patients and 193 control patients. Primary safety variables included best spectacle-corrected visual acuity (BSCVA) at 6 months and incidence of sight-threatening complications and adverse events. Primary effectiveness variables included percent reduction in manifest cylinder at 6 months, percent mean absolute reduction in MRSE at 6 months, and rotation of meridian of LAL at 6 months. Percent of eyes with an uncorrected visual acuity (UCVA) of 20/20 or better at six months post-operatively compared between the LAL treatment group and the monofocal control group was a secondary endpoint.

The Light Adjustable Lens corrects down to 0.5 diopters of postoperative cylinder.

The LAL corrects down to 0.5 diopters of astigmatism, which is the lowest level approved to be treated.

The ability to treat 0.50 D of postoperative cylinder makes the Light Adjustable Lens the only IOL in the United States approved to correct this level of vision-altering astigmatism. Astigmatism of as little as 0.50 D can reduce visual acuity by one line, and the impact on dynamic, functional visual acuity and low-contrast acuity is even greater.1